• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>ESMO Open >Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
【2h】

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

机译：在欧盟（EU）中实现平等及时地获得创新抗癌药物：CECOG推动的多学科圆桌讨论会的摘要重点是东欧和东南欧国家

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Central European Cooperative Oncology Group (CECOG) and ‘ESMO Open—Cancer Horizons’ roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or otherwise affected by delayed and unequal access to innovative anticancer drugs. The approval process of drugs is well established and access delays can be caused directly or indirectly by national or regional decision-making processes on reimbursement. The two key aspects for those involved in reimbursement decisions are first the level of evidence required to decide and second pricing, which can be challenging for some innovative oncology compounds, especially in Eastern and South-Eastern European countries. Other important factors include: available healthcare budget; the structure and sophistication of healthcare authorities and health technology assessment processes; societal context and political will. From the point of view of the pharmaceutical industry, better alignment between stakeholders in the process and adaptive pathway initiatives is desirable. Key aspects for patients are improved access to clinical trials, preapproval availability and reports on real-world evidence. Restricted access limits oncologists’ daily work in Eastern and South-Eastern EU countries. The roundtable discussion suggested considering the sequencing of regulatory approval and reimbursement decisions together with more flexible contracting as a possible way forward. The panel concluded that early and regular dialogue between all stakeholders including regulators, payers, patient stakeholders and industry is required to improve the situation.
机译：中欧肿瘤合作研究小组（CECOG）和“ ESMO癌症开放视野”圆桌会议将来自几个欧盟（EU）国家的利益相关者召集在一起，他们参与了药物开发，药物授权和报销，或受到创新性抗癌药物延迟和不平等获取的影响毒品。药品的批准程序已经很好地建立，获取或使用的延误可能是由国家或地区有关报销的决策程序直接或间接造成的。参与补偿决策的人员的两个关键方面是：决策所需的证据水平；其次，对于某些创新的肿瘤化合物，尤其是在东欧和东南欧国家，这可能会带来挑战。其他重要因素包括：可用的医疗保健预算；卫生保健机构的结构和复杂程度以及卫生技术评估过程；社会背景和政治意愿。从制药行业的角度来看，希望流程中的利益相关者与适应性途径计划之间更好地保持一致。患者的关键方面是改善获得临床试验的机会，预先批准的可用性以及有关真实证据的报告。受限访问限制了东欧和东南欧国家的肿瘤学家的日常工作。圆桌讨论建议考虑按法规批准和补偿决定的顺序以及更灵活的签约作为可能的前进方式。该小组的结论是，需要改善监管机构，付款人，患者利益相关方和行业之间所有利益相关方之间的定期对话。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号